This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19
by Zacks Equity Research
Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.
Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants
by Zacks Equity Research
Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.
Is a Surprise Coming for Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization
by Zacks Equity Research
Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes
by Zacks Equity Research
Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.
J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
by Zacks Equity Research
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
by Zacks Equity Research
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY).
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study
by Zacks Equity Research
Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.
Company News for Jan 12, 2021
by Zacks Equity Research
Companies in the news are: MESO, ODP, LLY, AZZ
Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
by Zacks Equity Research
Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.
Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs
by Zacks Equity Research
Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease
by Zacks Equity Research
If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.